 |
|
Prognostic Clinicopathologic Factors in Cutaneous T-cell Lymphoma
Rosa M. Martí, MD;
Teresa Estrach, MD;
Juan C. Reverter, MD;
José M. Mascaró, MD
Arch Dermatol. 1991;127(10):1511-1516.
Abstract
| |
• Influence of clinicopathologic data on survival was analyzed in 43 patients with cutaneous T-cell lymphoma. The median age was 66 years; 35 were male and eight female. The extent of the disease, established according to a modification of the TNM system, was as follows: T1, three patients; T2, 15; T3,14; T4,11; N0, 15; N1,28; M0, 38; M1,5; B0, 37; and B1, six. The first treatment applied after staging was skin-limited therapy in seven patients and different regimens of systemic chemotherapy in 29. Seven patients received no treatment or only topical corticosteroids and tars. Median follow-up was 26 months. Nineteen patients died, with a median survival of 36.3 months. The prognostic value of age, sex, delay of diagnosis and staging, pruritus, number of sites of clinically enlarged lymph nodes, results of staging and TNM classification, erythrocyte sedimentation rate, peripheral blood cell count, liver function tests, serum lactate dehydrogenase levels, protein electrophoresis, presence of epidermotropism, thickness of cutaneous infiltrate, blastic cell percentage, mitotic index, cellular density, cutaneous eosinophilia, and follicular mucinosis was studied. Multivariate analysis (proportional hazard model with covariates) indicated that the major prognostic factors in patients with cutaneous T-cell lymphoma are as (1) in a clinical model, the T category of TNM classification and the serum lactate dehydrogenase value; and (2) in a clinicopathologic model, the T category of TNM classification and the thickness of cutaneous infiltrate (measured in 10-1 mm from the granular layer to the lower limit of the infiltrate) of the clinically thickest lesion.
(Arch Dermatol. 1991;127:1511-1516)
Author Affiliations
From the Departments of Dermatology (Drs Martí, Estrach, and Mascaró) and Hematology (Dr Reverter), Hospital Clinic i Provincial of Barcelona, Spain.
Footnotes
Accepted for publication March 25, 1991.
Presented before the International Symposium of Cutaneous Lymphoma, Copenhagen, Denmark, October 28-30, 1988; and the 48th Annual Meeting of the American Academy of Dermatology, San Francisco, Calif, December 2-7, 1989.
Reprints not available.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
Olsen et al.
Blood 2007;110:1713-1722.
ABSTRACT
| FULL TEXT
Prognostic Value of Blood Eosinophilia in Primary Cutaneous T-Cell Lymphomas
Tancrede-Bohin et al.
Arch Dermatol 2004;140:1057-1061.
ABSTRACT
| FULL TEXT
Long-term Outcome of 525 Patients With Mycosis Fungoides and Sezary Syndrome: Clinical Prognostic Factors and Risk for Disease Progression
Kim et al.
Arch Dermatol 2003;139:857-866.
ABSTRACT
| FULL TEXT
Memorials and Mandates for Cutaneous Lymphomas
Heald
Arch Dermatol 2003;139:926-928.
FULL TEXT
Treatment of Cutaneous T-Cell Lymphoma With Combined Immunomodulatory Therapy: A 14-Year Experience at a Single Institution
Suchin et al.
Arch Dermatol 2002;138:1054-1060.
ABSTRACT
| FULL TEXT
Clinical Characteristics and Outcome of Patients With Extracutaneous Mycosis Fungoides
de Coninck et al.
JCO 2001;19:779-784.
ABSTRACT
| FULL TEXT
Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma
Scarisbrick et al.
Blood 2001;97:624-630.
ABSTRACT
| FULL TEXT
Primary Cutaneous T-Cell Lymphoma: Review and Current Concepts
Siegel et al.
JCO 2000;18:2908-2925.
ABSTRACT
| FULL TEXT
Tumor Burden Index as a Prognostic Tool for Cutaneous T-Cell Lymphoma: A New Concept
Schmid et al.
Arch Dermatol 1999;135:1204-1208.
ABSTRACT
| FULL TEXT
Prognostic Significance of a Polymerase Chain Reaction-Detectable Dominant T-Lymphocyte Clone in Cutaneous Lesions of Patients With Mycosis Fungoides
Delfau-Larue et al.
Blood 1998;92:3376-3380.
ABSTRACT
| FULL TEXT
Clinical Stage IA (Limited Patch and Plaque) Mycosis Fungoides: A Long-term Outcome Analysis
Kim et al.
Arch Dermatol 1996;132:1309-1313.
ABSTRACT
Prognostic Factors in Erythrodermic Mycosis Fungoides and the Sezary Syndrome
Kim et al.
Arch Dermatol 1995;131:1003-1008.
ABSTRACT
|
